{
  "first_published_at": "2012-08-20", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON180635", 
  "title": "Ondansetron (Zofran): risk of QTc prolongation – important new intravenous dose restriction", 
  "tags": "{\"parsed_therapeutic\": [\"anaesthesia-intensive-care\", \"gi-hepatology-pancreatic-disorders\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Anaesthesia and intensive care\", \"GI, hepatology and pancreatic disorders\"]}", 
  "_document_number": 105, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "anaesthesia-intensive-care", 
    "gi-hepatology-pancreatic-disorders"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Ondansetron (Zofran): risk of QTc prolongation &#8211; important new intravenous dose restriction</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The new maximum single intravenous dose of ondansetron for the management of chemotherapy-induced nausea and vomiting (CINV) in adults is now 16 mg (infused over at least 15 minutes).-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>The new maximum single intravenous dose of ondansetron for the management of chemotherapy-induced nausea and vomiting (CINV) in adults is now 16 mg (infused over at least 15 minutes).<br>\nThis restriction follows a review of new study data, which showed that there is a greater risk of prolongation of the electrocardiographic-corrected QT interval (QTc), a known side effect of ondansetron, when it is used at the higher doses previously authorised for CINV.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting.</p>\n\n<p>In a study in healthy adults, ondansetron 32 mg given intravenously (IV) over 15 minutes caused a maximum mean QTc prolongation of 19.57 (upper 90% confidence interval 21.49) milliseconds. This dose may therefore result in a clinically significant degree of QT prolongation in certain individuals.</p>\n\n<p>Ondansetron 8 mg IV over 15 minutes caused a QTc prolongation of 5.84 (upper 90% CI 7.76) milliseconds &#8211; this level of prolongation is not usually associated with increased risk of cardiac arrhythmias.</p>\n\n<p>Extrapolating from these results it was predicted that ondansetron 16 mg IV over 15 minutes would cause a QTC prolongation of 9.1 (upper 95% CI 11.2) milliseconds, an extent that is not usually associated with increased risk of cardiac arrhythmias.</p>\n\n<p>Prolongation of the QTc can lead to Torsade de Pointes (TdP), a potentially life-threatening cardiac arrhythmia. Although no cases of TdP were observed in the study, TdP has been reported in association with the use of ondansetron in clinical practice.</p>\n\n<div class=\"dull_highlight\">\n<h3>Advice to healthcare professionals:</h3>\n\n<ul>\n<li>A single dose of intravenous ondansetron given for the management of chemotherapy-induced nausea and vomiting in adults must not exceed 16 mg (infused over at least 15 minutes)</li>\n</ul>\n\n<ul>\n<li>Ondansetron should be avoided in patients with congenital long QT syndrome.</li>\n\n<li>Caution must be used if administering ondansetron to patients with risk factors for QT interval prolongation or cardiac arrhythmias. These include: electrolyte abnormalities; use of other medicines that prolong the QT interval (including cytotoxic drugs) or may lead to electrolyte abnormalities; congestive heart failure; bradyarrhythmias; and use of medicines which lower the heart rate</li>\n\n<li>Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration</li>\n</ul>\n</div>\n\n<p>The maximum recommended intravenous dose of ondansetron for the prevention and treatment of post-operative nausea and vomiting in adult patients is a single dose of 4 mg and this has not changed. In addition there are no changes in the recommended intravenous dosing for any indication in paediatric patients.</p>\n\n<p>There are no changes to the recommended dosing for oral or rectal ondansetron formulations in adult or paediatric patients in any indication.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101815\">Letter sent to healthcare professionals sent in August 2012</a></p>\n\n<p><a target=\"_blank\" href=\"/home/groups/pl-p/documents/drugsafetymessage/con178193.pdf\">Revised wording for ondansetron product information</a></p>\n\n<p>BNF section <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/129637.htm\">4.6: Drugs used in nausea and vertigo</a></p>\n\n<p><em>Article citation: Drug safety Update August 2012, vol 6 issue 1: A2</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting.</p>\n\n<p>In a study in healthy adults, ondansetron 32 mg given intravenously (IV) over 15 minutes caused a maximum mean QTc prolongation of 19.57 (upper 90% confidence interval 21.49) milliseconds. This dose may therefore result in a clinically significant degree of QT prolongation in certain individuals.</p>\n\n<p>Ondansetron 8 mg IV over 15 minutes caused a QTc prolongation of 5.84 (upper 90% CI 7.76) milliseconds &#8211; this level of prolongation is not usually associated with increased risk of cardiac arrhythmias.</p>\n\n<p>Extrapolating from these results it was predicted that ondansetron 16 mg IV over 15 minutes would cause a QTC prolongation of 9.1 (upper 95% CI 11.2) milliseconds, an extent that is not usually associated with increased risk of cardiac arrhythmias.</p>\n\n<p>Prolongation of the QTc can lead to Torsade de Pointes (TdP), a potentially life-threatening cardiac arrhythmia. Although no cases of TdP were observed in the study, TdP has been reported in association with the use of ondansetron in clinical practice.</p>\n\n<div class=\"dull_highlight\">\n<h3>Advice to healthcare professionals:</h3>\n\n<ul>\n<li>A single dose of intravenous ondansetron given for the management of chemotherapy-induced nausea and vomiting in adults must not exceed 16 mg (infused over at least 15 minutes)</li>\n</ul>\n\n<ul>\n<li>Ondansetron should be avoided in patients with congenital long QT syndrome.</li>\n\n<li>Caution must be used if administering ondansetron to patients with risk factors for QT interval prolongation or cardiac arrhythmias. These include: electrolyte abnormalities; use of other medicines that prolong the QT interval (including cytotoxic drugs) or may lead to electrolyte abnormalities; congestive heart failure; bradyarrhythmias; and use of medicines which lower the heart rate</li>\n\n<li>Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration</li>\n</ul>\n</div>\n\n<p>The maximum recommended intravenous dose of ondansetron for the prevention and treatment of post-operative nausea and vomiting in adult patients is a single dose of 4 mg and this has not changed. In addition there are no changes in the recommended intravenous dosing for any indication in paediatric patients.</p>\n\n<p>There are no changes to the recommended dosing for oral or rectal ondansetron formulations in adult or paediatric patients in any indication.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101815\">Letter sent to healthcare professionals sent in August 2012</a></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con178193.pdf\">Revised wording for ondansetron product information</a></p>\n\n<p>BNF section <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/129637.htm\">4.6: Drugs used in nausea and vertigo</a></p>\n\n<p><em>Article citation: Drug safety Update August 2012, vol 6 issue 1: A2</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-08-01", 
  "date_last_modified": "2013-01-28", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Revised wording for ondansetron product information", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con178193.pdf", 
      "filename": "downloads/ec0415dd8c33a6d26604b6e1f39f4ee9b9c54acf/con178193.pdf", 
      "original_filename": "con178193.pdf"
    }
  ], 
  "_item_id": 105, 
  "summary": "The new maximum single intravenous dose of ondansetron for the management of chemotherapy-induced nausea and vomiting (CINV) in adults is now 16 mg (infused over at least 15 minutes).\nThis restriction follows a review of new study data, which showed that there is a greater risk of prolongation of the electrocardiographic-corrected QT interval (QTc), a known side effect of ondansetron, when it is used at the higher doses previously authorised for CINV.", 
  "body": "Article date: August 2012\n\nOndansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting.\n\nIn a study in healthy adults, ondansetron 32 mg given intravenously (IV) over 15 minutes caused a maximum mean QTc prolongation of 19.57 (upper 90% confidence interval 21.49) milliseconds. This dose may therefore result in a clinically significant degree of QT prolongation in certain individuals.\n\nOndansetron 8 mg IV over 15 minutes caused a QTc prolongation of 5.84 (upper 90% CI 7.76) milliseconds – this level of prolongation is not usually associated with increased risk of cardiac arrhythmias.\n\nExtrapolating from these results it was predicted that ondansetron 16 mg IV over 15 minutes would cause a QTC prolongation of 9.1 (upper 95% CI 11.2) milliseconds, an extent that is not usually associated with increased risk of cardiac arrhythmias.\n\nProlongation of the QTc can lead to Torsade de Pointes (TdP), a potentially life-threatening cardiac arrhythmia. Although no cases of TdP were observed in the study, TdP has been reported in association with the use of ondansetron in clinical practice.\n\n### Advice to healthcare professionals:  \n  \n  * A single dose of intravenous ondansetron given for the management of chemotherapy-induced nausea and vomiting in adults must not exceed 16 mg (infused over at least 15 minutes)  \n  * Ondansetron should be avoided in patients with congenital long QT syndrome.  \n  * Caution must be used if administering ondansetron to patients with risk factors for QT interval prolongation or cardiac arrhythmias. These include: electrolyte abnormalities; use of other medicines that prolong the QT interval (including cytotoxic drugs) or may lead to electrolyte abnormalities; congestive heart failure; bradyarrhythmias; and use of medicines which lower the heart rate  \n  * Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration  \n  \nThe maximum recommended intravenous dose of ondansetron for the prevention and treatment of post-operative nausea and vomiting in adult patients is a single dose of 4 mg and this has not changed. In addition there are no changes in the recommended intravenous dosing for any indication in paediatric patients.\n\nThere are no changes to the recommended dosing for oral or rectal ondansetron formulations in adult or paediatric patients in any indication.\n\nFurther information:\n\n[Letter sent to healthcare professionals sent in August 2012](https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101815)\n\n[ASSET_TAG](#ASSET0)\n\nBNF section [4.6: Drugs used in nausea and vertigo](http://www.medicinescomplete.com/mc/bnf/current/129637.htm)\n\nArticle citation: Drug safety Update August 2012, vol 6 issue 1: A2\n"
}